# Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study

> **NCT00764868** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 269 (actual)

## Conditions studied

- ADHD

## Interventions

- **DRUG:** Lisdexamfetamine Dimesylate (LDX)

## Key facts

- **NCT ID:** NCT00764868
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11-13
- **Primary completion:** 2010-04-22
- **Final completion:** 2010-04-22
- **Target enrollment:** 269 (ACTUAL)
- **Last updated:** 2021-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00764868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00764868, "Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00764868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*